Company news
Yd Bio Limited (NASDAQ:YDES) news
Every Yd Bio Limited press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026
August 31, 2026
YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research
August 4, 2026
YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada
July 28, 2026
YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations
July 2, 2026
YD Bio Limited Reports Full Year 2025 Financial Results
April 30, 2026
YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized ...
March 31, 2026
YD Bio Limited CEO Dr. Ethan Shen Details Strategic Roadmap for Integrated Oncology Ecosystem
March 17, 2026
YD Bio Limited Announces Strategic Partnership with YC Biotech Co., Ltd. to Establish a Taiwan-U.S. Dual-Core Regulatory Platform
February 25, 2026
YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe save Medical Cell Sciences and Technology Co., Ltd., Bolstering Leade...
January 30, 2026
YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leaders...
January 29, 2026
YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation–Driven AI Platforms for Cancer Diagnostics and Drug Development
January 6, 2026
YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap
January 5, 2026
YD Bio Limited Expands U.S. Presence with Newly Planned California Facilities and Operations Center
December 16, 2025
YD Bio Limited Showcases Its Innovative Diagnostic and Precision Medicine Portfolios at the 9th Healthcare EXPO TAIWAN
December 9, 2025
YD Bio Limited Expands OkaiDx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Rese...
December 2, 2025
YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics
November 24, 2025
YD Bio and EG BioMed Expand U.S. Access to OkaiDx™, a cfDNA‑Methylation Blood Test for Post‑Treatment Breast Cancer Monitoring
November 5, 2025
YD Bio Ltd. Rings Nasdaq Opening Bell to Celebrate Listing under Ticker YDES
October 20, 2025
YD Bio Business Partner EG Biomed Achieves CAP Accreditation, Advancing U.S. Clinical Testing Capabilities
October 10, 2025
YD Bio Limited Reports Unaudited Half Year 2025 Financial Results
September 30, 2025
YD Bio Limited Announces Closing of Business Combination and Listing on the Nasdaq Global Market
August 29, 2025